 |
0 Diseases |  |
3 Trials |
|
3 Trials |  |
213 News |  |
| «12345 |
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Hafyera (paliperidone palmitate extended-release 6-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P3 trial: A Study of Paliperidone Palmitate 6-Month Formulation (clinicaltrials.gov) - Nov 17, 2017
P3, N=765, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation (clinicaltrials.gov) - Jun 5, 2017
P3, N=306, Active, not recruiting, Sponsor: Janssen-Cilag Ltd.
Recruiting --> Active, not recruiting
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - Aug 5, 2016
P3, N=275, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Active, not recruiting Phase classification: P4 --> P3
- |||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation (clinicaltrials.gov) - May 25, 2016
P3, N=300, Recruiting, Sponsor: Janssen-Cilag Ltd.
Phase classification: P4 --> P3 Not yet recruiting --> Recruiting
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P3 trial: A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation (clinicaltrials.gov) - May 13, 2016
P3, N=300, Recruiting, Sponsor: Janssen-Cilag Ltd.
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P3 trial: A Study of Transition to the Paliperidone Palmitate 3-Month Formulation In Participants With Schizophrenia Previously Stabilized on the Paliperidone Palmitate 1-Month Formulation (clinicaltrials.gov) - Mar 18, 2016
P3, N=300, Not yet recruiting, Sponsor: Janssen-Cilag International NV
- |||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment open: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - Jul 16, 2015
P4, N=275, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - Jun 9, 2015
P4, N=275, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Phase classification: P3 --> P4
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - May 1, 2015
P3, N=275, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
- ||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Trial completion, Head-to-Head: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Apr 16, 2015
P3, N=1430, Completed, Sponsor: Janssen Research & Development, LLC
Phase classification: P3 --> P4 Active, not recruiting --> Completed
- ||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Trial completion: A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia (clinicaltrials.gov) - Jun 24, 2014
P1, N=326, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Trial primary completion date: A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - May 25, 2014
P3, N=511, Completed, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Trial primary completion date: Aug 2014 --> Apr 2014
- ||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Trial completion date: A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - May 25, 2014
P3, N=511, Completed, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Aug 2014 --> Apr 2014 Trial completion date: Nov 2014 --> Apr 2014
- ||||||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Trial completion: A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - May 25, 2014
P3, N=511, Completed, Sponsor: Janssen Research & Development, LLC
Trial completion date: Nov 2014 --> Apr 2014 Active, not recruiting --> Completed
- ||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment closed, Head-to-Head: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Nov 24, 2013
P3, N=1431, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment closed: A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Sep 3, 2013
P3, N=511, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- || Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment closed: A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia (clinicaltrials.gov) - Jan 14, 2013
P1, N=325, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P1 trial: A Study to Assess the Pharmacokinetics, Safety, and Tolerability of Paliperidone Palmitate in Patients With Schizophrenia (clinicaltrials.gov) - Mar 19, 2012
P1, N=325, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P3 trial: A Study of Paliperidone Palmitate 3 Month Formulation for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Feb 7, 2012
P3, N=511, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
New P3 trial, Head-to-Head: Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Patients With Schizophrenia (clinicaltrials.gov) - Jan 22, 2012
P3, N=1431, Active, not recruiting, Sponsor: Janssen Research & Development, LLC